Neoplasma. 2018;65(1):161-166. doi: 10.4149/neo_2018_102.
Lung cancer is the leading cause of cancer morbidity and mortality around world. Heat shock protein beta-1 (HSPB1) expression is aberrantly increased in non-small cell lung cancer (NSCLC) patients. However, the roles of HSPB1 expression in the prognosis of NSCLC are still elusive. In this study, we investigated the prognostic roles of HSPB1 in NSCLC by using "The Kaplan-Meier plotter" (KM plotter) database. Our data indicated that HSPB1 mRNA low expression was correlated to better overall survival (OS) for all NSCLC patients, hazard ratio (HR) 1.41 (1.24-1.61), p=1.1e-7, and better OS in lung adenocarcinoma (LUAD) patients, HR 1.81 (1.42-2.32), p=1.5e-06, but not in lung squamous cell carcinoma (LUSC) patients, HR 1.21 (0.94-1.55), p=0.14. In addition, mRNA low expression of HSPB1 is also significantly associated with better OS of NSCLC patients in different smoking status, in different chemotherapy status, in clinical stage I et II, as well as patients with successful surgery treatment. Our results indicated that HSPB1 expression may have distinct prognostic values in NSCLC patients, and may provide an effective clinical strategy to accurately predict the prognosis of NSCLC patients.
肺癌是全球癌症发病率和死亡率的主要原因。热休克蛋白 beta-1（HSPB1）在非小细胞肺癌（NSCLC）患者中的表达异常增加。然而，HSPB1 表达在 NSCLC 预后中的作用仍不清楚。在这项研究中，我们使用“Kaplan-Meier plotter”（KM plotter）数据库研究了 HSPB1 在 NSCLC 中的预后作用。我们的数据表明，HSPB1 mRNA 低表达与所有 NSCLC 患者的总生存期（OS）更好相关，风险比（HR）为 1.41（1.24-1.61），p=1.1e-7，以及肺腺癌（LUAD）患者的 OS 更好，HR 为 1.81（1.42-2.32），p=1.5e-06，但在肺鳞癌（LUSC）患者中则不然，HR 为 1.21（0.94-1.55），p=0.14。此外，HSPB1 mRNA 低表达也与不同吸烟状态、不同化疗状态、临床分期 I 期和 II 期以及手术治疗成功的 NSCLC 患者的 OS 更好显著相关。我们的结果表明，HSPB1 表达在 NSCLC 患者中可能具有不同的预后价值，并可能为准确预测 NSCLC 患者的预后提供有效的临床策略。
